Accueil   Diary - News   All news VALBIOTIS receives US and European TOTUM-070 patent for reducing hypercholesterolemia

VALBIOTIS receives US and European TOTUM-070 patent for reducing hypercholesterolemia

  • TOTUM-070 exclusivity guaranteed in the United States and in Europe for reducing blood LDL-cholesterol levels, a cardiovascular disease risk factor;

  • Intellectual property rights protecting the composition of the TOTUM-070 active substance for food and pharmaceutical applications;

  • A milestone in the further development of TOTUM-070, in the search for commercial partnerships and in receiving approval for health claims in Europe and North America.

 

La Rochelle, September 14, 2020 (5:40 pm CEST) VALBIOTIS (FR0013254851 - ALVAL, eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, has announced that it has obtained an American and European patent for TOTUM-070, its active substance dedicated to reducing LDL-cholesterol in the blood (“bad cholesterol”).

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree